Primary biliary cholangitis (PBC) has typically been considered a rare condition, with a pooled global estimated incidence of ...

Danziten is a twice daily, oral medication that inhibits the BCR-ABL tyrosine kinase. Nilotinib was originally approved under the brand name Tasigna; it is currently indicated for adults and pediatric ...

Ipsen presents 3 late-breaking presentations and 8 abstracts across rare cholestatic liver disease portfolio at AASLD 2024Iqirvo approved for use in the U.S. in June 2024, in the E.U. in September ...